American Journal of Psychiatry Audio

Život na zemlji

Each episode of AJP Audio brings you an in-depth look at one of the articles featured in that month's issue of The American Journal of Psychiatry, the official journal of the American Psychiatric Association. Wide-ranging interviews with article authors cover the background, rationale, main findings, and future implications of the research. This podcast is subject to the Terms of Use at ww.psychiatry.org. The views and opinions expressed in this podcast are those of the individual speakers only and do not necessarily represent the views of the American Psychiatric Association, its officers, trustees, or members. The content of this podcast is provided for general informational purposes only and is not intended as, and shall not be understood or construed as, medical or any other type of professional advice nor does it represent any statement of the standard of care. We strongly recommend that any listener follow the advice of physicians directly involved in their care and contact their local emergency response number for any medical emergency. The information within this podcast is provided as-is and is not guaranteed to be correct, complete, or accurate.
00:00
00:00

Rezime epizode

Dr. Charles Conway (Washington University School of Medicine, St. Louis) joins the podcast to discuss the RECOVER trial, a RCT that looked at vagus nerve stimulation and its effects on profoundly treatment resistant depression. Following that, AJP Editor-in-Chief Dr. Ned Kalin is joined by the October issue guest editor, Dr. William McDonald (Emory University, Atlanta) to discuss the rest of the October issue, which focuses on neuromodulation and precision therapeutics. 00:42 Conway interview 02:34 Quality of life 05:13 Ethical considerations of a sham arm in this population 07:00 Timing and VNS treatment 08:03 Clinical implications 09:02 Limitations 10:12 Further research 11:30 McDonald and Kalin interview 13:50 Song et al. 14:08 Li et al. 15:44 Donnery et al. 16:38 Valiengo et al. 17:28 Rush 20:03 Mahmoudi 22:37 Conway et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to…

Epizode

347-

October 2026: The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, and Future Directions

Dr. Charles Conway (Washington University School of Medicine, St. Louis) joins the podcast to discuss the RECOVER trial, a RCT that looked at vagus nerve stimulation and its effects on profoundly treatment resistant depression. Following that, AJP Editor-in-Chief Dr. Ned Kalin is joined by the October issue guest editor, Dr. William McDonald (Emory University, Atlanta) to discuss the rest of the October issue, which focuses on neuromodulation and precision therapeutics. 00:42 Conway interview 02:34 Quality of life 05:13 Ethical considerations of a sham arm in this population 07:00 Timing and VNS treatment 08:03 Clinical implications 09:02 Limitations 10:12 Further research 11:30 McDonald and Kalin interview 13:50 Song et al. 14:08 Li et al. 15:44 Donnery et al. 16:38 Valiengo et al. 17:28 Rush 20:03 Mahmoudi 22:37 Conway et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to…

01 окт. 2026
346-

September 2026: Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial

Dr. Heon-Jeong Lee (Korea University, Seoul) joins AJP Audio to discuss an app-based intervention designed to help individuals with mood disorders regulate their circadian rhythms to prevent recurrence of mood episodes. Afterwards, Dr. Ned Kalin will join us again to discuss the rest of the September issue of the Journal, which takes a close look at clinical treatment. 00:44 Findings 01:42 How the app works 03:05 Differences between the app and traditional lifestyle advice 04:14 Ethics surrounding shame treatment arms 05:43 Broader applicability of the intervention 06:50 Limitations 08:19 Immediate clinical implications 09:33 Further research 10:08 Kalin interview 10:27 Yeom et al. 16:02 Schacht et al. 20:31 Khosravani et al. 24:52 Peterson et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric…

01 сеп. 2026
345-

August 2026: Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure

Dr. Deepak Cyril D'Souza (Yale University School of Medicine) joins the podcast to discuss a study looking at two cohorts of patients hospitalized with first instances of psychosis, one with cannabis exposure and one without. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin takes us through the August issue of the Journal, which takes a look at issues surrounding schizophrenia spectrum disorder, from the clinical to basic science. 00:40 D'Souza interview 02:38 Subtyping and schizophrenia spectrum disorder 04:19 Relapse and long-term implications for cannabis induced psychosis 05:43 Improvements in cognition 08:03 Differences between the groups 09:26 Greater access and greater potency of cannabis products 11:29 Further research 13:45 Kalin interview 13:59 D'Souza et al. 21:34 Forsyth et al. 27:36 Enwright et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here.…

01 авг. 2026
344-

July 2026: Social Determinants of Health in Psychiatric Disorders: Exciting Opportunities for Biopsychosocial Research and Clinical Care

Dr. Dilip Jeste (Social Determinants of Health Network, La Jolla, CA) joins the podcast to discuss how social determinants of health interact with treatment for psychiatric disorders. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin once again puts the rest of the July issue into context. 00:31 Impacts of social determinants of health on psychiatric disorders, research, and clinical care 04:43 Health related social needs versus social determinants of health 08:47 Loneliness as a risk factor 12:36 A clinician's role in societal factors 14:47 Mechanistic understandings social determinants and the exposome 18:17 Further research 22:25 Kalin interview 22:30 Jeste and Gyan 23:33 Blundell et al. 28:03 Yang et al. 32:20 Van der Meer et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse…

01 јул. 2026
343-

June 2026: Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Dr. Jason Tucciarone and Dr. Alan Schatzberg (Stanford University, Stanford, CA) join AJP Audio to discuss the use of low-dose buprenorphine as an adjunctive therapy to extend the anti-suicidal effects of ketamine treatment in patients with major depressive disorder and suicidal ideation. AJP Editor-in-Chief Dr. Ned Kalin joins to discuss the rest of the June issue of the Journal, which takes a close look at issues surrounding suicide and severe depression. 01:20 Tucciarone and Schatzberg interview 03:36 Disparity between effects on suicidal ideation and antidepressant ratings 05:36 Ethics of placebo and ketamine in patients with suicidal ideation 08:28 Immediate clinical implications 11:40 Limitations 14:10 Further research 16:19 Kalin interview 16:24 Tucciarone et al. 20:39 Rovers et al. 24:30 Jelen et al. Transcript Board-certified psychiatrists, if you're seeking meaningful inpatient work with real clinical autonomy, consider becoming the Clinical Director for a 16-bed behavioral health hospital in…

01 јун. 2026